Diagnostics firms should still get fair valuation in IPOs: Thyrocare’s Velumani
Advertisement

Diagnostics firms should still get fair valuation in IPOs: Thyrocare’s Velumani

By Joseph Rai

  • 16 Nov 2018
Premium
Diagnostics firms should still get fair valuation in IPOs: Thyrocare’s Velumani
Arokiaswamy Velumani

Thyrocare Technologies Ltd had made a spectacular debut on the stock exchanges two years ago. But its share prices have fallen from the highs, prompting the diagnostics company to buy the stock back from the market to show its confidence. Its larger peer Dr Lal PathLabs Ltd, which became the ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.
Advertisement
Advertisement
Google News Icon

Google News

Follow VCCircle on Google News for the latest updates on Business and Startup News